Savara Overview

  • Founded
  • 2007

Founded
  • Status
  • Public

  • Employees
  • 35

Employees
  • Stock Symbol
  • SVRA

Stock Symbol
  • Investments
  • 3

  • Share Price
  • $2.64

  • (As of Monday Closing)

Savara General Information

Description

Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

Contact Information

Formerly Known As
Savara Pharmaceuticals
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Drug Delivery
Stock Exchange
NAS
Primary Office
  • 6836 Bee Cave Road, Building 3
  • Suite 201
  • Austin, TX 78746
  • United States
+1 (512) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Savara Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.64 $2.75 $1.02 - $2.82 $304M 114M 175K -$0.25

Savara Financials Summary

In Thousands,
USD
TTM 30-Sep-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 60,369 (3,926) (6,883) 146,739
Revenue 0 0 257 0
EBITDA (37,631) (40,365) (47,440) (77,093)
Net Income (39,160) (43,014) (49,615) (78,173)
Total Assets 147,758 176,598 97,745 136,203
Total Debt 26,092 25,791 25,283 25,552
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Savara Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Savara‘s full profile, request access.

Request a free trial

Savara Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Savara‘s full profile, request access.

Request a free trial

Savara Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's lead program, molgr
Biotechnology
Austin, TX
35 As of 2022
00000
000000000 00000

000000

onsequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum
0000000000000
Westlake Village, CA
000 As of 0000
00000
000000 - 000 00000

0000 0

quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequ
0000 000000000
Austin, TX
00 As of 0000
000.00
0000000000 0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Savara Competitors (22)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
MannKind Formerly VC-backed Westlake Village, CA 000 00000 000000 - 000 00000
0000 000000000000 Venture Capital-Backed Austin, TX 00 000.00 0000000000 0 000.00
0000000 Formerly VC-backed Stevenage, United Kingdom 00 00000 000000&0 00000
0000000000 0000000 Venture Capital-Backed Brighton, United Kingdom 00 0000 000000 - 000 0000
000000 000000 Formerly VC-backed Morristown, NJ 0 00.000 000000 - 000 00.000
You’re viewing 5 of 22 competitors. Get the full list »

Savara Patents

Savara Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20200115412-A1 Separation of vancomycin and its degradation products Inactive 15-Oct-2018 0000000000
EP-3866829-A1 Separation of vancomycin and its degradation products Inactive 15-Oct-2018 00000000
US-20140014107-A1 Methods to administer formulations of aminoglycoside and fosfomycin combination for treatment of ventilator associated pneumonia (vap) and ventilator associated tracheal (vat) bronchitis Active 12-Jul-2011 00000000000
US-8820323-B2 Methods to administer formulations of aminoglycoside and fosfomycin combination for treatment of ventilator associated pneumonia (vap) and ventilator associated tracheal (vat) bronchitis Inactive 12-Jul-2011 00000000000 00
US-8826904-B2 Formulations of aminoglycoside and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (vap) and ventilator associated tracheal (vat) bronchitis Inactive 12-Jul-2011 A61K31/7036 00
To view Savara’s complete patent history, request access »

Savara Executive Team (14)

Name Title Board Seat Contact Info
David Lowrance Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Anne Erickson Senior Vice President & Executive, Investor Relations
Raymond Pratt MD Chief Medical Officer
You’re viewing 3 of 14 executive team members. Get the full list »

Savara Board Members (10)

Name Representing Role Since
An van Es-Johansson MD Self Board Member 000 0000
David Ramsay Savara Board Member 000 0000
Joseph McCracken Self Board Member 000 0000
Matthew Pauls JD Self Chairman & Chief Executive Officer 000 0000
Nevan Elam JD Self Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Savara Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Savara Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Savara‘s full profile, request access.

Request a free trial

Savara Investments & Acquisitions (3)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 00000 25-Jul-2018 000000000 Buildings and Property 000000 00
0000 00000000 27-Apr-2017 0000000000 00000 Pharmaceuticals 000000 00
Serendex Pharmaceuticals 15-Jul-2016 Merger/Acquisition 000.00 Buildings and Property 000000 00
To view Savara’s complete investments and acquisitions history, request access »

Savara Subsidiaries (1)

Company Name Industry Location Founded
000000 Pharmaceuticals Austin, TX 0000
To view Savara’s complete subsidiaries history, request access »

Savara ESG

Risk Overview

Risk Rating

Updated May, 27, 2021

33.36 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.00

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 14,042

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 947

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 427

Rank

00.00

Percentile

To view Savara’s complete esg history, request access »